glp-1/gip dual agonist lilly The Sustained Effects of a GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes Retatrutide: Eli Lilly's GLP-1 Triple

doi: 10.1016/S0140-6736(19)31149-3 55 GastaldelliACusiKFernndez LandLBrayRBrouwersBRodrguez

People lost, on average, two to six pounds while taking Trulicity

1 This mechanism suggested that GLP-1 would be an excellent target for controlling postprandial blood glucose levels

Patients have even reported having to undergo gastric bypass as a result of severe medication-induced gastroparesis

Baldissera F

Ethics declarations Funding VSS is supported by a Department of Medicine Eliot Phillipson Clinician-Scientist Training Program, a Banting and Best Diabetes Centre Postdoctoral Fellowship at the University of Toronto and a Canadian Institutes of Health Research (CIHR) Frederick Banting and Charles Best Canada Graduate Scholarships Doctoral Research Award